PTC Therapeutics (PTCT) PT Raised to $50 at Goldman Sachs

Goldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $50.00 while maintaining a Sell rating.

The analyst comments "Positive initial Sephience launch kinetics plus DMD resilience drive a topline beat; R&D day to elucidate pipeline plans outside of BD. We expect PTCT shares to react positively as early Sephience sales topped Street estimates (though this was generally expected). Ahead, we will continue to monitor the Sephience launch, and await updates on the votoplam (PTC518) program in Huntington's disease after planned FDA meeting in 4Q25 as well as potential updates on diversifying the pipeline in the upcoming R&D day in December. Maintain Sell but raise 12-months PT to $50."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Boeing lands two U.S. defense contracts worth over $711M
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters